AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31870424 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual guidance on restricting dietary salt intake by a physician
Number of subjects: 200
Study 31870424 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment only
Number of subjects: 200
Study 27940395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynaecological teaching associates (GTAs)
Number of subjects: 492
Study 27940395 — intervention group
Group type: COMPARATOR
Intervention: Conventional pelvic manikin based teaching
Number of subjects: 492
Study 25903195 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based moderate intensity walking intervention
Number of subjects: 0
Study 25903195 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 23337606 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐Entropy monitoring
Number of subjects: 50
Study 23337606 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 50
Study 21343219 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease self-management intervention implemented by nurses
Number of subjects: 0
Study 21343219 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 19702927 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐focused therapy (FFT)
Number of subjects: 10
Study 17931576 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based interactive training using video modeling and mastery learning instructional design
Number of subjects: 62
Study 17931576 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 15480372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (hand washing, glove use, avoiding intimate contact)
Number of subjects: 166
Study 15480372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instructions)
Number of subjects: 166
Study 15480372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (for women attempting pregnancy with a child shedding CMV)
Number of subjects: 166
Study 15480372 — intervention group
Group type: COMPARATOR
Intervention: Control group (for women already pregnant at enrollment)
Number of subjects: 166
Study 11509190 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked marijuana (8.4 and 16.9 mg THC)
Number of subjects: 13
Study 11509190 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg)
Number of subjects: 13
Study 9146840 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering MS (informed)
Number of subjects: 69
Study 9146840 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering MS (non-informed)
Number of subjects: 69
Study 9146840 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering TBI (informed)
Number of subjects: 69
Study 9146840 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering TBI (non-informed)
Number of subjects: 69
Study 9146840 — intervention group
Group type: COMPARATOR
Intervention: Non-malingering controls
Number of subjects: 69
Study 8131435 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding via nasoenteric tube
Number of subjects: 10
Study 8131435 — intervention group
Group type: EXPERIMENTAL
Intervention: Large meal
Number of subjects: 10
Study 8131435 — intervention group
Group type: COMPARATOR
Intervention: Sham feeding
Number of subjects: 10
Study 3312933 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled coffee
Number of subjects: 42
Study 3312933 — intervention group
Group type: COMPARATOR
Intervention: Filtered coffee
Number of subjects: 42
Study 3312933 — intervention group
Group type: COMPARATOR
Intervention: Tea
Number of subjects: 42
Study 31189655 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk polar lipids (3 or 5 g-PL/day)
Number of subjects: 58
Study 31189655 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk polar lipids (5 g-PL/day)
Number of subjects: 58
Study 31189655 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk polar lipids
Number of subjects: 58
Study 30104806 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed endotracheal suctioning protocol
Number of subjects: 90
Study 30104806 — intervention group
Group type: COMPARATOR
Intervention: Routine endotracheal suctioning protocol
Number of subjects: 90
Study 27609846 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous parecoxib sodium followed by oral celecoxib
Number of subjects: 246
Study 27609846 — intervention group
Group type: COMPARATOR
Intervention: Placebo with opioids as rescue treatment
Number of subjects: 246
Study 25907853 — intervention group
Group type: EXPERIMENTAL
Intervention: ICARUSS model of integrated care
Number of subjects: 1000
Study 25907853 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000
Study 23725316 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional caries management with best practice prevention
Number of subjects: 1461
Study 23725316 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological management of caries with best practice prevention
Number of subjects: 1461
Study 23725316 — intervention group
Group type: COMPARATOR
Intervention: Best practice prevention alone
Number of subjects: 1461
Study 20578610 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine tablet at the dose of 5 microg/kg
Number of subjects: 60
Study 20578610 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 60
Study 18400709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate and cocoa (37-g dark chocolate bar and 8 ounces of artificially sweetened cocoa beverage daily for 6 weeks
Number of subjects: 101
Study 18400709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar placebo products daily for 6 weeks)
Number of subjects: 101
Study 16102908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate
Number of subjects: 98
Study 16102908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion
Number of subjects: 98
Study 16102908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12527318 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful infusion of hypertonic saline in the FDI muscle
Number of subjects: 10
Study 12527318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain combined with dual stimulation (electrical stimulation of the FDI motor point paired with TMS)
Number of subjects: 10
Study 12527318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual stimulation (electrical stimulation of the FDI motor point paired with TMS)
Number of subjects: 10
Study 12527318 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 10
Study 12527318 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation of the FDI
Number of subjects: 10
Study 12527318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar-evoked M-waves
Number of subjects: 10
Study 10588558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg)
Number of subjects: 30
Study 10588558 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (2.5 mg/kg)
Number of subjects: 30
Study 10588558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8906985 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials with increased sample sizes over time
Number of subjects: 386
Study 8906985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials in gastroenterology, cardiology, or oncology
Number of subjects: 386
Study 8906985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with binary outcomes
Number of subjects: 386
Study 8906985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with significant results
Number of subjects: 386
Study 1748037 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II gastrectomy
Number of subjects: 22
Study 1748037 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrectomy
Number of subjects: 22
Study 1748037 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II gastrectomy with persistent HP infection
Number of subjects: 22
Study 1748037 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 22
Study 7107083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephapirin
Number of subjects: 217
Study 7107083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 217
Study 7107083 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin
Number of subjects: 217
Study 7107083 — intervention group
Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 217
Study 3987769 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry salbutamol powder (400 micrograms)
Number of subjects: 22
Study 3987769 — intervention group
Group type: COMPARATOR
Intervention: Pressurized salbutamol aerosol (200 micrograms)
Number of subjects: 22
Study 29781900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (NAFL) treatment on one half of the face
Number of subjects: 18
Study 29781900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isotretinoin (10 mg/day)
Number of subjects: 18
Study 29781900 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFL treatment
Number of subjects: 18
Study 27046471 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic Calcium Phosphate (BCP) combined with Platelet-Rich Plasma (PRP)
Number of subjects: 20
Study 27046471 — intervention group
Group type: COMPARATOR
Intervention: Demineralized Bovine Bone Matrix (DBBM) combined with Platelet-Rich Plasma (PRP)
Number of subjects: 20
Study 23946152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted danoprevir (DNVr) 100/100 mg twice/day
Number of subjects: 18
Study 23946152 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance therapy (MMT) alone
Number of subjects: 18
Study 22303473 — intervention group
Group type: EXPERIMENTAL
Intervention: Family meetings intervention (n=96)
Number of subjects: 192
Study 22303473 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=96)
Number of subjects: 192
Study 20393352 — intervention group
Group type: EXPERIMENTAL
Intervention: Back squat or hang clean (midthigh) with a load equal to their 5 repetition maximum (5RM)
Number of subjects: 16
Study 20393352 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 or 5-minute rest interval after resistance exercise
Number of subjects: 16
Study 20393352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground reaction force (GRF) measurement
Number of subjects: 16
Study 18758201 — intervention group
Group type: COMPARATOR
Intervention: OxyContin tablets (controlled‐release oxycodone hydrochloride: 5, 10, 20, and 40 mg)
Number of subjects: 0
Study 15917111 — intervention group
Group type: EXPERIMENTAL
Intervention: PCECV (Purified Chick Embryo Cell Vaccine) administered intradermally at 0.1 mL with antigen corresponding to 0.32 IU per intramuscular dose
Number of subjects: 0
Study 15917111 — intervention group
Group type: COMPARATOR
Intervention: Current WHO recommendations for vaccine potency (2.5 IU per intramuscular dose)
Number of subjects: 0
Study 12903979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumpkin (n = 6)
Number of subjects: 14
Study 12903979 — intervention group
Group type: COMPARATOR
Intervention: Spinach (n = 8)
Number of subjects: 14
Study 10327202 — intervention group
Group type: EXPERIMENTAL
Intervention: Illusory bar seen rotating with the inducing gratings
Number of subjects: 0
Study 10327202 — intervention group
Group type: EXPERIMENTAL
Intervention: Illusory bar seen as a stationary and opaque tape
Number of subjects: 0
Study 8600871 — intervention group
Group type: EXPERIMENTAL
Intervention: Home program of physical therapy (6-week program including ROM exercises, low resistance isometric and eccentric exercises of hip abductors)
Number of subjects: 23
Study 8600871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no programs)
Number of subjects: 23
Study 8600871 — intervention group
Group type: EXPERIMENTAL
Intervention: Home program of physical therapy (all programs for group B)
Number of subjects: 23
Study 1817942 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Midazolam sedation
Number of subjects: 0
Study 1817942 — intervention group
Group type: COMPARATOR
Intervention: Oral Midazolam sedation
Number of subjects: 0
Study 7258126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (1.8 g daily for 10 children, 1.5 g daily for 10 children)
Number of subjects: 40
Study 7258126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 40
Study 7258126 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplemental ascorbic acid)
Number of subjects: 40
Study 31173468 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment for HBV (HBV DNA < 20 IU/mL after 48 weeks)
Number of subjects: 264
Study 31173468 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment for HCV (SVR-12)
Number of subjects: 264
Study 31173468 — intervention group
Group type: COMPARATOR
Intervention: Baseline PRO scores in HBV
Number of subjects: 264
Study 31173468 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment PRO scores
Number of subjects: 264
Study 30411114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity treated with catalase after external bleaching and then filled with composite resin
Number of subjects: 40
Study 30411114 — intervention group
Group type: COMPARATOR
Intervention: Composite resin filling immediately after external bleaching
Number of subjects: 40
Study 30411114 — intervention group
Group type: COMPARATOR
Intervention: Immersed in artificial saliva for 3 weeks after external bleaching, then filling with composite resin
Number of subjects: 40
Study 30411114 — intervention group
Group type: COMPARATOR
Intervention: Direct composite resin filling without bleaching
Number of subjects: 40
Study 26142456 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude hypoxia (5400 m)
Number of subjects: 39
Study 23988398 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care (blinded random allocation to trial treatment or placebo)
Number of subjects: 1084
Study 23988398 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PEFR, baseline heart rate, other serious illness, PEFR change, heart rate change
Number of subjects: 1084
Study 23988398 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PEFR, baseline heart rate, baseline respiratory rate, other serious illness, PEFR change, heart rate change
Number of subjects: 1084
Study 22264599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive adaptation training combined with assertive community treatment (CAT+ACT)
Number of subjects: 62
Study 22264599 — intervention group
Group type: COMPARATOR
Intervention: Assertive community treatment alone (ACT)
Number of subjects: 62
Study 19846267 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 1500
Study 19846267 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 1500
Study 19846267 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir plus Prednisolone
Number of subjects: 1500
Study 19846267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 17211096 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-71 treatment for 12 months
Number of subjects: 0
Study 17211096 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-71 treatment
Number of subjects: 0
Study 17211096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15526112 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogalvanic stimulation (EGS) twice a week
Number of subjects: 53
Study 15526112 — intervention group
Group type: COMPARATOR
Intervention: Local injection of 40-mg triamcinolone acetonide mix with 1 ml 2% lidocaine
Number of subjects: 53
Study 11564134 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (10 mg)
Number of subjects: 24
Study 11564134 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (as racemate)
Number of subjects: 24
Study 9784078 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 19
Study 9784078 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 19
Study 9784078 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beverages
Number of subjects: 19
Study 9784078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea
Number of subjects: 19
Study 9784078 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 19
Study 9784078 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (100 mg caffeine)
Number of subjects: 19
Study 7843964 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt water baths with 15% synthetic Dead Seas salt (Psorisal)
Number of subjects: 40
Study 7843964 — intervention group
Group type: COMPARATOR
Intervention: 3% NaCl solution baths
Number of subjects: 40
Study 3152422 — intervention group
Group type: EXPERIMENTAL
Intervention: IV sodium nitroprusside
Number of subjects: 3
Study 3152422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside with oral captopril pretreatment
Number of subjects: 3
Study 3152422 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nitroglycerin
Number of subjects: 3
Study 3152422 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3
Study 31820008 — intervention group
Group type: EXPERIMENTAL
Intervention: Swing door technique
Number of subjects: 60
Study 31820008 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 60
Study 30131382 — intervention group
Group type: EXPERIMENTAL
Intervention: ASITN/SIR collateral score assessment by 19 observers
Number of subjects: 19
Study 30131382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomized score for collateral assessment
Number of subjects: 19
Study 28985328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target <120 mm Hg)
Number of subjects: 2488
Study 28985328 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target <140 mm Hg)
Number of subjects: 2488
Study 28985328 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall model (both treatment arms)
Number of subjects: 2488
Study 25352300 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus adefovir dipivoxil (ADV) combination therapy (COMBO)
Number of subjects: 358
Study 25352300 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine optimization strategy (OPTIMIZE)
Number of subjects: 358
Study 25352300 — intervention group
Group type: COMPARATOR
Intervention: lamivudine monotherapy (MONO)
Number of subjects: 358
Study 25352300 — intervention group
Group type: COMPARATOR
Intervention: lamivudine monotherapy (MONO) with early virological response
Number of subjects: 358
Study 23314393 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg amphetamine (AMPH)
Number of subjects: 60
Study 23314393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22283037 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Neonatal and Childhood Illness (IMNCI)
Number of subjects: 1102573
Study 22283037 — intervention group
Group type: COMPARATOR
Intervention: Control districts
Number of subjects: 1102573
Study 19772869 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (ESZ)
Number of subjects: 39
Study 19772869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17186003 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 7
Study 17186003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 16036080 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 0
Study 11928585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (75 g)
Number of subjects: 6000
Study 11928585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glycemia according to ADA recommendation
Number of subjects: 6000
Study 11928585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test and glycemia at 120 min exceeding 11.1 mmol/l
Number of subjects: 6000
Study 9328501 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological debriefing (PD)
Number of subjects: 133
Study 9328501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 133
Study 15125277 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 82
Study 15125277 — intervention group
Group type: COMPARATOR
Intervention: Control (no steroids)
Number of subjects: 82
Study 2877576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous famotidine
Number of subjects: 8
Study 2877576 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous famotidine
Number of subjects: 8
Study 2877576 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral famotidine
Number of subjects: 8
Study 2877576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30168257 — intervention group
Group type: EXPERIMENTAL
Intervention: Nav1 module
Number of subjects: 21
Study 30168257 — intervention group
Group type: EXPERIMENTAL
Intervention: For1 module
Number of subjects: 21
Study 30168257 — intervention group
Group type: EXPERIMENTAL
Intervention: ERM1 module
Number of subjects: 21
Study 30168257 — intervention group
Group type: EXPERIMENTAL
Intervention: ERM2 module
Number of subjects: 21
Study 30168257 — intervention group
Group type: COMPARATOR
Intervention: Vit1 module
Number of subjects: 21
Study 30168257 — intervention group
Group type: COMPARATOR
Intervention: Vit2 module
Number of subjects: 21
Study 29910118 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized reminder/recall for vaccination
Number of subjects: 50000
Study 29910118 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50000
Study 27514161 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Assisted Vaginal Hysterectomy (LAVH)
Number of subjects: 187
Study 27514161 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 187
Study 25443650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt table standing, electrical stimulation and ankle splinting
Number of subjects: 36
Study 25443650 — intervention group
Group type: COMPARATOR
Intervention: Tilt table standing alone
Number of subjects: 36